Skip to main content

Maria Mar Hernandez Guillamon

Senior Researcher, Neurovascular Research Lab, VHIR.

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Maria Mar Hernandez Guillamon

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Senior Researcher, Neurovascular Research Lab, VHIR.

Dr. Mar Hernández-Guillamon has dedicated her career to the study of cerebral amyloid angiopathy (CAA) and other pathologies associated with the deposition of amyloid-beta (Abeta). In 2013, she was awarded by Carlos III Spanish Health Institute with the Miguel Servet contract to establish the Cerebral Amyloidosis line of research at VHIR. Her group has positioned in forefront of the Abeta-pathologies field, studying the molecular mechanisms involved in the Abeta transport and metabolism using in vitro and in vivo models. Her lab has also dedicated to the clinical research and discovery of biomarkers associated with CAA and other cerebrovascular diseases. The translational research developed by Dr. Hernandez-Guillamon's group has allowed the achievement of important aims to date, as demonstrated by the scientific production obtained (h-index= 35, 80 publications, >3700 citations) and the continuous leadership of national and international projects.

Research lines

L5 Cerebral Amyloid Angiopathy

Current project: 

Involment of proteolytic systems in the progression of Cerebral Amyloid Angiopathy


Cerebral amyloid angiopathy (CAA) is produced by the accumulation of ß-amyloid protein within the meningeal and brain vessels. It is the second leading cause of cerebral hemorrhages. However, nowadays, factors related to brain bleedings following amyloid deposition are largely unknown. The understanding of the mollecular mechanisms that lead to cerebral hemorrhage may be the basis for future treatments.

Previous evidences of our group have shown that Matrix Metal•loproteinases (MMPs) are related to brain bleeding. Now, we aim to investigate the relationship between these proteolytic systems and the appearance of intracraneal hemorrages in CAA.


Our study includes:


1) The identification of both tissue and plasma biomarkers for the diagnosis and prognosis of CAA-related hemorrhages.


2) The search of the genetic markers related to proteolytic systems that could determine the risk of suffering a recurrence in CAA.


We are studying a cohort of probable CAA patients that have been recruited in Hospital Vall d’Hebron in collaboration with the Stroke Project of the Cerebrovascular Diseases Study Group (Spanish Society of Neurology).


3) The study of MMPs role in ß-amyloid stimulated vascular cells in vitro.


Cultured cells of the neurovascular unit are challenged with different ß-amyloid peptides and the implication of MMPs in ß-amyloid cleavage and cell toxicity are studied using cellular and molecular biology methodology.


For this purpose, we use the human cerebral endothelial cell line hCMEC/D3, primary cultures of human leptomeningeal smooth muscle cells and rat/mouse glial and neuronal cultures.



Thioflavin-S staining of fibillar ß-amyloid within brain vessels of CAA patient’s sections.



Related bibliography:


1)  Hernández-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, García-Bonilla  L, Fernández-Cadenas I, Borrell-Pagès M, Boada M, Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J Neurosci Res. 2009 Jul;87(9):2115-25.


2) Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006 Jun;37(6):1399-406.


3)  Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, Santamarina E, Quintana M, Monasterio J, Montaner J. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004 Jun;35(6):1316-22.


4) Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003 Feb 4;107(4):598-603.



Collaborations:

Mercè Boada

Fundació ACE, Barcelona, Spain.

www.fundacioace.com/


Jorge Ghiso and Agueda Rostagno

Pathology Dept. Langone Medical Center. NYU

New York, US.


Ignacio Romero

Life Science Dept. Open University.

Milton Keynes, UK.

IP: Maria Mar Hernandez Guillamon

Projects

Papel de la proteína MFGE8 como potencial biomarcador y diana terapéutica en la angiopatía amiloide cerebral

IP: Maria Mar Hernandez Guillamon
Collaborators: Berta Paez Montserrat, Kerrie Adrián Campbell, Jessica Camacho Soriano, Anas Chaachou Charradi, Olalla Pancorbo Rosal
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI23/00082
Duration: 01/01/2024 - 31/12/2026

Tejiendo Ciencia

IP: Ariadna Laguna Tuset
Collaborators: Anna Santamaria Margalef, Maria Mar Hernandez Guillamon, Sara Mas Assens
Funding agency: Fundación Española Ciencia y Tecnología (FECYT)
Funding: 15000
Reference: FCT-23-19804
Duration: 01/09/2024 - 31/08/2025

Implication of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy

IP: Maria Mar Hernandez Guillamon
Collaborators: Berta Paez Montserrat, Laia Perez Lasarte
Funding agency: FUNDACIÓN JOSEP PALAU FRANCÀS
Funding: 68873.32
Reference: VHIRFRANCAS/PREDOC/2022
Duration: 01/02/2023 - 31/01/2026

Malalties neurovasculars

IP: Anna Rosell Novel
Collaborators: Mercedes Arrúe Gonzalo, Joan Montaner Villalonga, Marcel Lamana Vallverdu, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Paula Garcia Rodriguez, Miguel García Gabilondo, Nicolas Garcia Rodriguez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00656
Duration: 01/01/2022 - 30/06/2025

Related news

For three days, the III Stroke Congress of the national RICORS-ICTUS network and a symposium focused on cerebral haemorrhage were held.

The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Marcos Prieto, Susana

Marcos Prieto, Susana

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.